Stock NBIX NEUROCRINE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
133.1 USD -0.46% Intraday chart for Neurocrine Biosciences, Inc. -1.15% +0.99%
Jun. 05 Transcript : Neurocrine Biosciences, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 02:30 PM
Jun. 03 Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing
Neurocrine Biosciences Says CEO Kevin Gorman Retiring
Neurocrine founder-CEO Gorman to retire in October
Neurocrine CEO set to retire
Neurocrine Biosciences, Inc. Announces Dr. Kyle Gano as Director, Effective October 11, 2024
Neurocrine Biosciences Announces CEO Changes
Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing
Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis
Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing
Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst? Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
Neurocrine Biosciences Presents CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024
Neurocrine Biosciences Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Jump Pre-Bell
Neurocrine Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024
Neurocrine Gets FDA Approval for Ingrezza Sprinkle Capsules; Shares Rise After-Hours
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. News Neurocrine Biosciences, Inc.
  5. Other languages